Regarding cardiovascular outcomes in HF patients with CKD, in the PARADIGM‐HF trial, LCZ696 reduced the risk of major composite endpoints (cardiovascular disease‐related deaths and HF hospitalization) by 20% and all‐cause mortality by 16% compared with enalapril, and eGFR (30–60 mL/min/1.73 m2) and urinary albumin/creatinine ratio did not affect the improvement of LCZ696 on HF hospitalization and cardiovascular‐related deaths.18, 19, 20. Here, ALB is linked to chronic kidney disease.